HomeMarketsSharesDarioHealth Corp.

Trade DarioHealth Corp. - DRIO CFD

6.04+10.02%
The chart shows the DRIO stock price data over the last 1 day, with a current price of 6.04, a high of 5.79, and a low of 5.78.
Low: 5.78High: 5.79
Sellers:
50%
Buyers:
50%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.25
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.022207 %
(-$4.44)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02221%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000015 %
(-$0.00)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.00002%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close5.42
Open5.78
1-Year Change-64.25%
Day's Range5.78 - 5.79

Trade DarioHealth Corp. - DRIO

About DarioHealth Corp

DarioHealth Corp.(DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. DarioHealth products include Dario blood glucose monitoring, Dario Blood Pressure Monitoring System, and Dario Smart Scale. The Dario blood glucose monitoring device is a system that measure sugar levels. The Dario Smart Scale is a blood pressure monitoring system used to measure blood pressure and stored in a digital logbook in the Dario App. It offers modular platform integrating digital therapeutics, coaching, devices, and care providers. Its suite of offerings includes Dario Tools, DarioEngage, and Dario Loop.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, DarioHealth Corp revenues increased from $7.6M to $20.5M. Net loss applicable to common stockholders increased from $33.1M to $78.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Marketing and Pre-Production Cost increase from $12.5M to $33.7M (expense).

Equity composition

Common Stock $0.0001 Par, Shares auth. 45M and o/s 19,240,234 issd. Insiders own approx. 14.03% (after the IPO). If no information is provided, use TBA. 10/14 1-for-5 reverse stock split. 03/2016, 1-For-18 Reverse Stock Split.

Latest shares articles

A GameStop store in Portland, Oregon
GameStop stock forecast: debt exchange, Q2 profit
GameStop is a US video-game retailer. In Q2 fiscal 2026, net sales fell to $790.2m, while operating income rose to $160.2m. Explore third-party GME price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:06, 7 October 2026
Freenet stock forecast
Freenet stock forecast: revenue rises, EBITDA falls
Freenet reported first-half 2026 revenue of €1,512.9 million, up 24.7% year on year, while adjusted EBITDA fell 5.9% to €242.2 million and 2026 guidance was maintained. Explore third-party FNTN price targets and technicals. Past performance is not a reliable indicator of future results.
12:41, 7 October 2026
Hims & Hers Health stock forecast
Hims & Hers Health stock forecast: FDA GLP-1 warning
Hims & Hers Health is a US telehealth company. In August 2026, the FDA issued a warning concerning unapproved compounded GLP-1 weight-loss drugs. Explore third-party HIMS price targets and technical analysis. Past performance is not a reliable indicator of future results.
12:18, 7 October 2026
Arm Holdings stock forecast
Arm Holdings stock forecast: Haas flags AI demand
Arm Holdings is a UK-based semiconductor company. Chief executive Rene Haas said AI and data-centre demand showed no signs of slowing. Explore third-party ARM price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:43, 6 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready